Semaglutide Quick Reference (5 mg vial)
Research context: mechanisms, human and preclinical evidence, limitations and precautions are in How this works and References. The calculator (Spanish) converts any other volume.
Semaglutide Dosage Chart (5 mg vial)
Dosing & Reconstitution Guide
Educational guide for reconstitution and weekly dosing
Standard Weekly Escalation Schedule (1 mL = ~5 mg/mL)
| Study phase | Weekly dose | Units per injection (mL) |
|---|---|---|
| Weeks 1 to 4 | 250 mcg | 5 units (0.05 mL) |
| Weeks 5 to 8 | 500 mcg | 10 units (0.10 mL) |
| Weeks 9 to 12 | 1 mg (1000 mcg) | 20 units (0.20 mL) |
| Weeks 13 to 16 | 1.7 mg (1700 mcg) | 34 units (0.34 mL) |
| Weeks 17+ | 2.4 mg (2400 mcg) | 48 units (0.48 mL) |
Frequency: Once weekly, subcutaneously, at a consistent time.
Reconstitution Steps
- Draw 1 mL of bacteriostatic water with a sterile syringe.1
- Inject slowly down the vial wall; avoid shaking to prevent foaming.2
- Gently swirl or roll until fully dissolved (clear solution).3
- Label with the reconstitution date and refrigerate at 2–8 °C, protected from light; use within 4 weeks.4
Important: this guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.
U-100 Conversion Table (1 mL = 5 mg/mL)
| U-100 units | Volume | Contains | Yield per vial |
|---|---|---|---|
| 2 | 0.02 mL | 100 mcg | 50 injections |
| 5 | 0.05 mL | 250 mcg | 20 injections |
| 10 | 0.10 mL | 500 mcg | 10 injections |
| 20 | 0.20 mL | 1 mg (1000 mcg) | 5 injections |
| 30 | 0.30 mL | 1.5 mg (1500 mcg) | 3 injections |
| 50 | 0.50 mL | 2.5 mg (2500 mcg) | 2 injections |
| 100 | 1.00 mL | 5 mg (5000 mcg) | 1 injection |
This section describes which dose a study or reference source used and what it measured. It is not a recommendation or an administration schedule. A trial dose belongs to its population, duration and supervision and does not transfer to anyone outside that context.
Supplies Needed
Straightforward 12- and 24-week planning for a 5 mg vial at 5 mg/mL.
Semaglutide vials (5 mg each)
- Standard Weekly Escalation Schedule, 12 weeks: Minimum 2 vials (7 mg required).
- Standard Weekly Escalation Schedule, 24 weeks: Minimum 7 vials (33 mg required).
U-100 syringes (1 mL)
- Standard Weekly Escalation Schedule, 12 weeks: 12 new syringes for 12 injections.
- Standard Weekly Escalation Schedule, 24 weeks: 24 new syringes for 24 injections.
Bacteriostatic water
- Standard Weekly Escalation Schedule, 12 weeks: 2 mL total (1 mL per vial) → 1 × 3 mL vials.
- Standard Weekly Escalation Schedule, 24 weeks: 7 mL total (1 mL per vial) → 3 × 3 mL vials.
Alcohol swabs
- Standard Weekly Escalation Schedule, 12 weeks: 24 minimum; one box of 100 covers the calculation.
- Standard Weekly Escalation Schedule, 24 weeks: 48 minimum; one box of 100 covers the calculation.
Sharps container: one appropriately sized. Stability planning: totals are minimum arithmetic quantities; follow the product documentation for sterility, storage, handling loss and discard timing.
Semaglutide 5mgView in store
Bacteriostatic water 3 mLView in storeStore links may earn a commission. A supplier page is not scientific evidence or proof of suitability for human use.
Semaglutide Vial and Research Context
- Reconstitute: add 1 mL of bacteriostatic water to produce 5 mg/mL.
- Frequency in the source: once weekly, subcutaneously.
- Described range: schedules run from 250 mcg to 2.4 mg (2400 mcg) per injection.
- Easy measuring: 1 U-100 unit = 0.01 mL = 50 mcg.
- Vial size: the 5 mg label is total nominal content, not a per-injection amount.
- Vial coverage: at 250 mcg per injection one vial supplies 20 injections; at 2.4 mg (2400 mcg) it supplies 2. These are mass calculations, not storage periods.
Protocol Overview
Quick reference for the schedules shared by the cited literature.
- Frequency: once weekly.
- Concentration: 5 mg in 1 mL = 5 mg/mL.
- Unit conversion: 1 U-100 unit = 50 mcg.
Dosing Schedule
The tables keep each approach separate.
- Standard Weekly Escalation Schedule: 250 mcg, 500 mcg, 1 mg (1000 mcg), 1.7 mg (1700 mcg), 2.4 mg (2400 mcg), in phases (once weekly).
- Measurement: use the units and mL shown beside each amount.
Storage Instructions
- Lyophilized (unopened): −20 °C for long-term storage; 2–8 °C if used within weeks. Protected from light.
- Reconstituted: 2–8 °C, do not freeze. Use within the documented period (typically up to 4 weeks with bacteriostatic water).
- Handling: do not shake; avoid temperature cycling; label with date and concentration.
- Discard: cloudy solutions, particulates or expired preparations are discarded.
More detail in the storage guide (Spanish).
Important Notes
- Research only: the referenced compounds are sold for laboratory research. Nothing here is medical advice or an administration schedule.
- Evidence: chart amounts come from published trials or approved prescribing information, cited in References.
- Above 100 units: a 1 mL U-100 syringe cannot hold them; split across syringes or reconstitute with less volume.
- Accuracy: concentration depends on the actual volume added; measure the diluent with a syringe, not by eye.
- Verification: confirm vial contents against the batch certificate of analysis before calculating.
How This Works
Semaglutide is a synthetic analog of glucagon-like peptide-1 (GLP-1) with 94% homology to native human GLP-1. This 31-amino-acid peptide (MW: 4113.58 Da) incorporates strategic modifications that extend its half-life:
Structural Modifications:
Substitution of Alanine by 2-aminoisobutyric acid (AIB) at position 8
Acylation at Lysine-26 with a C18 fatty acid via a spacer
A hydrophobic side chain that facilitates binding to serum albumin (>99%)
Molecular Mechanisms:
- GLP-1R receptor: Selective activation in pancreatic β-cells, hypothalamus, and gastrointestinal tract
cAMP/PKA pathway: Increase in intracellular cyclic AMP → glucose-dependent insulin secretion - Glucagon Suppression: Pancreatic alpha-cell inhibition during hyperglycemia
Gastric Emptying: Delay Mediated by Vagal Signaling (70% Reduction) - Central Satiety Activation of POMC/CART neurons in the hypothalamic arcuate nucleus
Advanced Pharmacokinetics:
- Subcutaneous bioavailability: 89%
- Tmáx: 1-3 days post-injection
- Median life 165-184 hours (weekly administration)
- Renal clearance: <1% (primary proteolytic degradation)
- Steady state: 4-5 weeks
Research Applications
Metabolic Regulation in Experimental Models
Glycemic Control
- HbA1c reduction: 1.5–2.01 TP3T in diabetic models (Aroda et al., 2017)
- Increased insulin secretion: 200-300% during oral tolerance testing
- Improves insulin sensitivity: Reduced HOMA-IR index 40-50%
Body Weight Modulation:
- Weight reduction: 12-15% in long-term studies (68 weeks) (Wilding et al., 2021)
- Visceral fat loss: 25-30% above the subcutaneous tissue
- Lean mass preservation: A loss of 85-90% corresponds to adipose tissue
Cardiovascular Effects (SUSTAIN Studies):
- Reduction of MACE events: 26% vs. placebo (Marso et al., 2016)
- Decrease in systolic blood pressure: 4-6 mmHg
- Improves lipid profile: triglyceride reduction 15-20%
Neuroprotection and Cognitive Function
Neurodegeneration Models:
- Reduction of beta-amyloid plaques in Alzheimer's models: 30-40% (Cai et al., 2018)
- Prevention of dopaminergic neuronal loss in Parkinson's
- Attenuation of neuroinflammation: decrease in IL-6, TNF-α (50–60%)
Synaptic Plasticity:
- Increase in BDNF (Brain-Derived Neurotrophic Factor): 25-35%
- Improved hippocampal long-term potentiation (LTP)
- Neurogenesis in the dentate gyrus: increase 40%
Injection Technique in Research
- Route in the studies: subcutaneous, in abdominal or thigh adipose tissue, rotating the site.
- Syringe: 1 mL U-100 (100 units); read in units, not mL.
- Asepsis: alcohol swab on the stopper and the site; a new syringe per injection.
- Drawing: purge air, draw the units from the chart and verify before withdrawing the needle from the vial.
Full guide: U-100 syringes and reading units (Spanish).
Research FAQ
Q: How does Semaglutide compare to other GLP-1 agonists? R: It presents a higher affinity for GLP-1R (EC50: 0.38 nM vs 1-5 nM for liraglutide) and a 7-fold longer half-life, allowing for weekly administration versus daily.
P: Is it compatible for research in combination with insulin? A: Yes, studies show a synergistic effect on glycemic control with a 30% reduction in the required insulin dose (Aroda et al., 2017).
Q: What biochemical markers should be monitored in prolonged studies? R: Plasma glucose, HbA1c, C-peptide, glucagon, serum lipase, renal function (creatinine, BUN), and inflammatory markers (CRP, IL-6).
P: What is the optimal timing for metabolic evaluations? R: Steady state reached in 4-5 weeks; continuous glycemic measurements require at least 8 weeks for full effects.
Research Note
All content on this page is technical and educational. It describes how a vial is reconstituted, how a syringe is read and which amounts the cited sources describe. It does not replace the supervision of a qualified researcher or the judgment of a health professional, and it is not intended to diagnose, treat, cure or prevent any disease.
References
- Wilding JPH et al. N Engl J Med 2021;384(11):989-1002. PMID 33567185
- Aroda VR, et al. (2017) “Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine” – Lancet Diabetes Endocrinol 5(5):355-366. [PubMed: 28344112]
- Wilding JPH, et al. (2021) “Once-Weekly Semaglutide in Adults with Overweight or Obesity” - The New England Journal of Medicine 384(11):989-1002. [PubMed: 33567185]
- Marso SP, et al. (2016) “Semaglutide and Cardiovascular Outcomes in Diabetes” – The New England Journal of Medicine 375(19):1834-1844. [PubMed: 27633186]
- Cai HY, et al. (2018) “GLP-1 treatment protects Alzheimer model through enhancing neuronal insulin signaling” – Brain Res 1678:64-72. [PubMed: 29128461]
- Novo Nordisk Research (2017) “Pharmacokinetic properties of semaglutide” – Diabetes Obes Metab 19(1):140-147.